Eloxx PharmaceuticalsELOX -0.76%17 3-Year ROIIC % is -513.41 as of Dec. 2025. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 1,321 Biotechnology companies, Eloxx Pharmaceuticals ranks worse than 89.55% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Eloxx Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -513.41%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Eloxx Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
ELOX's 3-Year ROIIC % is ranked worse than 89.55% of 1321
companies
in the Biotechnology industry
Industry Median: -4.44
vs ELOX: -513.41
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Eloxx Pharmaceuticals 3-Year ROIIC % Related Terms
Eloxx Pharmaceuticals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Eloxx Pharmaceuticals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELOX vs ESLA, RNXT, ABVC: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Eloxx Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eloxx Pharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Eloxx Pharmaceuticals's 3-Year ROIIC % falls into.
Eloxx Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -6.438 (Dec. 2025) - -34.419 (Dec. 2022) )
/
( 12.816 (Dec. 2025) - 18.266 (Dec. 2022) )
=
27.981
/
-5.45
=
-513.41%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Eloxx Pharmaceuticals (ELOX) has a 3-Year ROIIC % of -513.41 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Eloxx Pharmaceuticals and its competitors. According to the industry distribution chart, Eloxx Pharmaceuticals ranks #1183 out of 1321 companies in the Biotechnology industry, placing it in the top 89.6%.
Is Eloxx Pharmaceuticals' 3-Year ROIIC % too high?
Eloxx Pharmaceuticals' current 3-Year ROIIC % is -513.41. Based on the distribution chart, Eloxx Pharmaceuticals ranks #1183 out of 1321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Eloxx Pharmaceuticals' 3-Year ROIIC % compare to ESLA and RNXT?
According to the Biotechnology industry distribution chart, Eloxx Pharmaceuticals ranks #1183 out of 1321 companies for 3-Year ROIIC %. This places Eloxx Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Eloxx Pharmaceuticals and its competitors. Eloxx Pharmaceuticals's current 3-Year ROIIC % is -513.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eloxx Pharmaceuticals stock overvalued right now?
Eloxx Pharmaceuticals (ELOX) has a current 3-Year ROIIC % of -513.41. The current 3-Year ROIIC % is -513.41. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current 3-Year ROIIC % is -513.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
17GF Score
Get the complete analysis for ELOX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELOX has been successfully added to your 
